Home Medizin Neue Entdeckung könnte die Möglichkeiten für den medizinischen Einsatz von Botox erweitern

Neue Entdeckung könnte die Möglichkeiten für den medizinischen Einsatz von Botox erweitern

von NFI Redaktion

Researchers at PSI have discovered a surprising method that may expand the medical applications of the drug Botulinumtoxin A1, better known as Botox. They have developed antibody-like proteins that accelerate the enzyme’s effect on the transmission of nerve signals, suggesting that Botox could relieve pain more quickly than previously thought. The study has been published in the journal Naturkommunikation.

Botulinumneurotoxin A1, commonly known as Botox, is a nerve toxin produced by bacteria. It has gained public attention due to its cosmetic use, primarily to reduce facial wrinkles by blocking nerve-muscle signal transmission. However, Botox is also widely used in therapeutic medicine to treat conditions associated with muscle spasms, faulty nerve signals, and more. It is crucial to administer this potent drug with precision, as an overdose can result in dangerous paralysis.

Different Types of Botox

Botox is divided into seven serotype groups, labeled A to G. The type A1, which is commonly used in cosmetics, is known to be effective in pain therapy and orthopedics, offering important treatment options. Types E and F work faster than types A and B, indicating potential novel uses in various disease treatments. The serotypes are mainly produced by different strains of bacteria known as Clostridium botulinum.

Surprising Findings

Researchers aimed to find DARPins that bind selectively to the catalytic domain of Botox serotype A1, a key component responsible for its nerve signal effect. Surprisingly, the findings showed that these DARPin proteins accelerated the toxic effect of Botox.

New Opportunities for Botox Therapy

The results indicate that DARPins could expand the possible uses of Botulinumneurotoxin A1 and offer new opportunities for treating a range of diseases, including pain management. Adding these DARPins to Botox may accelerate its effectiveness, leading to prolonged relief. This unexpected result opens doors for future medical developments.


Paul Scherrer Institut (PSI)

Journal Reference:

Leka, O., et al. (2023). Ein DARPin fördert einen schnelleren Wirkungseintritt des Botulinumneurotoxins A1. Naturkommunikation. doi.org/10.1038/s41467-023-44102-4.

Related Posts

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.